Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

COVID-19 vaccine coverage targets to inform reopening plans in a low incidence setting

Eamon Conway, View ORCID ProfileCamelia Walker, Chris Baker, View ORCID ProfileMichael Lydeamore, Gerard E. Ryan, Trish Campbell, Joel C. Miller, Max Yeung, Greg Kabashima, James Wood, Nic Rebuli, James M. McCaw, View ORCID ProfileJodie McVernon, Nick Golding, View ORCID ProfileDavid J. Price, Freya M. Shearer
doi: https://doi.org/10.1101/2022.12.04.22282996
Eamon Conway
1Walter and Eliza Hall Institute, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Camelia Walker
2School of Mathematics and Statistics, The University of Melbourne, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Camelia Walker
Chris Baker
2School of Mathematics and Statistics, The University of Melbourne, Melbourne, Australia
3Melbourne Centre for Data Science, The University of Melbourne, Melbourne, Australia
4Centre of Excellence for Biosecurity Risk Analysis, The University of Melbourne, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Lydeamore
5Department of Econometrics and Business Statistics, Monash University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michael Lydeamore
Gerard E. Ryan
6Telethon Kids Institute, Perth, Australia
7Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Trish Campbell
7Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia
8Department of Infectious Diseases at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joel C. Miller
9Department of Mathematics and Statistics, La Trobe University, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Max Yeung
10Quantium, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Greg Kabashima
10Quantium, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Wood
11School of Population Health, The University of New South Wales, Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nic Rebuli
11School of Population Health, The University of New South Wales, Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James M. McCaw
2School of Mathematics and Statistics, The University of Melbourne, Melbourne, Australia
7Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jodie McVernon
8Department of Infectious Diseases at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Australia
12Victorian Infectious Diseases Reference Laboratory Epidemiology Unit at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jodie McVernon
Nick Golding
6Telethon Kids Institute, Perth, Australia
13Curtin University, Perth, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David J. Price
7Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia
8Department of Infectious Diseases at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David J. Price
Freya M. Shearer
7Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: freya.shearer{at}unimelb.edu.au
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Since the emergence of SARS-CoV-2 in 2019 through to mid-2021, much of the Australian population lived in a COVID-19 free environment. This followed the broadly successful implementation of a strong suppression strategy, including international border closures. With the availability of COVID-19 vaccines in early 2021, the national government sought to transition from a state of minimal incidence and strong suppression activities to one of high vaccine coverage and reduced restrictions but with still-manageable transmission. This transition is articulated in the national “re-opening” plan released in July 2021. Here we report on the dynamic modelling study that directly informed policies within the national re-opening plan including the identification of priority age groups for vaccination, target vaccine coverage thresholds and the anticipated requirements for continued public health measures — assuming circulation of the Delta SARS-CoV-2 variant. Our findings demonstrated that adult vaccine coverage needed to be at least 70% to minimise public health and clinical impacts following the establishment of community transmission. They also supported the need for continued application of test-trace-isolate-quarantine and social measures during the vaccine roll-out phase and beyond.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was directly funded by the Australian Government Department of Health Office of Health Protection. Additional support was provided by the Australian Research Council (NG DECRA fellowship DE180100635) and the National Health and Medical Research Council of Australia through its Centres of Research Excellence (SPECTRUM, GNT1170960) and Investigator Grant Schemes (JMcV Principal Research Fellowship, GNT1117140; FMS Emerging Leader Fellowship, 2021/GNT2010051).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵† Joint first-authorship

  • ↵‡ Joint senior-authorship

Data Availability

No new datasets are presented in this research. Code to perform the analyses is available at

https://github.com/aus-covid-modelling/NationalCabinetModelling

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 06, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
COVID-19 vaccine coverage targets to inform reopening plans in a low incidence setting
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
COVID-19 vaccine coverage targets to inform reopening plans in a low incidence setting
Eamon Conway, Camelia Walker, Chris Baker, Michael Lydeamore, Gerard E. Ryan, Trish Campbell, Joel C. Miller, Max Yeung, Greg Kabashima, James Wood, Nic Rebuli, James M. McCaw, Jodie McVernon, Nick Golding, David J. Price, Freya M. Shearer
medRxiv 2022.12.04.22282996; doi: https://doi.org/10.1101/2022.12.04.22282996
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
COVID-19 vaccine coverage targets to inform reopening plans in a low incidence setting
Eamon Conway, Camelia Walker, Chris Baker, Michael Lydeamore, Gerard E. Ryan, Trish Campbell, Joel C. Miller, Max Yeung, Greg Kabashima, James Wood, Nic Rebuli, James M. McCaw, Jodie McVernon, Nick Golding, David J. Price, Freya M. Shearer
medRxiv 2022.12.04.22282996; doi: https://doi.org/10.1101/2022.12.04.22282996

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)